CURE - Direxion Daily Healthcare Bull 3X Shares
| Previous Close | 76.43 |
| Open | 76.99 |
| Bid | 0.00 x 800 |
| Ask | 78.58 x 800 |
| Day's Range | 76.75 - 77.72 |
| 52 Week Range | 43.28 - 80.51 |
| Volume | 68,156 |
| Avg. Volume | 88,457 |
| Net Assets | 148.24M |
| NAV | 76.43 |
| PE Ratio (TTM) | N/A |
| Yield | 0.43% |
| YTD Daily Total Return | 3.54% |
| Beta (5Y Monthly) | 2.60 |
| Expense Ratio (net) | 1.08% |
| Inception Date | 2011-06-15 |
- Benzinga
3 Leveraged Healthcare ETFs Soaring This Month
The new coronavirus from China has claimed more than 800 lives and there are now more than 37,000 documented cases of the respiratory illness worldwide, making it more deadly than the 2003 SARS epidemic. ...
- Zacks
Best & Worst Leveraged ETFs of Last Week
Inside the top-and-worst-performing leveraged ETFs of last week.
- Benzinga
Expert: 'I've had far fewer defensive conversations than I would have expected' About The Market
Benzinga: Taken the first few weeks of 2020 into account, what can you even say about this market right now? Jablonski: So, I think if we take a look at where we are today...December was one of the best months for stock gains in 50 years. For investors just trying to come in and evaluate, the valuations might be a little bit high and the risk of getting in them might be higher, too.
- ETF Trends
Healthcare Venture Capital Will Continue to Fuel M&A Activity
Merger and acquisitions (M&A) activity within the healthcare industry heightened last year, according to recent research data and this could feed into gains for M&A and healthcare-focused ETFs for traders sensing an opportunity. “The U.S. healthcare market saw a 14.4 percent increase in mergers and acquisitions from 2017-2018, fueled by soaring domestic venture capital investment – an all-time high of $130.9 billion invested in U.S.-based startups in 2018 alone,” a press release by Sage Growth Partners said. "Business opportunities in healthcare today are driven by two key factors – the industry's widespread waste and inefficiencies, and public and private sector mandates to reduce costs while increasing health outcomes," said Dan D'Orazio, SGP's CEO.
- Zacks
5 Top-Performing Leveraged ETFs of November
Inside the best five best leveraged ETFs of November.
- Simply Wall St.
Does Biocure Technology (CNSX:CURE) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
- Benzinga
It's Time To Consider Leveraged Healthcare ETFs
With one of the industry's marquee conferences recently ending, traders may want to consider the Direxion Daily Healthcare Bull 3X Shares (NYSE: CURE) and the Direxion Daily S&P Biotech Bull 3X Shares (NYSE: LABU). The American Society of Clinical Oncology Annual Meeting ended this week, which could bring CURE and LABU into focus for active traders.
- ETF Trends
Health Care ETFs Could be Cure for Trade War Blues
Whether the markets are roaring or experiencing doldrums, health care exchange-traded funds (ETFs) have been a paragon of reliability, and could be the safe haven investors need to cure the trade war blues. For traders, this could bode well for the Direxion Daily Healthcare Bull 3X ETF (CURE). In particular, the pharmaceutical business is experiencing a profit squeeze as a result of lesser-than-expected revenue from the sale of generic drugs.
- Simply Wall St.
How Much Of Biocure Technology Inc. (CNSX:CURE) Do Insiders Own?
If you want to know who really controls Biocure Technology Inc. (CNSX:CURE), then you'll have to look at the makeup of...
- ETF Trends
Health Care ETFs Get a Boost From Latest Jobs Report
Job growth in March made a comeback following a less-than-stellar February as 196,000 jobs were created as opposed to 175,000 expected by economists with a good portion coming from the health care sector, ...
- Newsfile
BiocurePharm, Korea ("BPK") Announces Closing of Private Placement
Vancouver, British Columbia--(Newsfile Corp. - February 28, 2019) - Biocure Technology Corp. (CSE:CURE) (OTCQB: BICTF) ("CURE" or the "Company") BiocurePharm, Korea ("BPK"), a wholly owned subsidiary of Biocure Technology Inc. ("CURE") is pleased to announce that it has closed its non-brokered private placement through its Korean Subsidiary BiocurePharm, Korea ("BPK"), BPK has issued 96,404 shares at $11.45 CAD per share for gross proceeds of $1,103,749. After the issuance of new BPK shares, CURE holds ...
